COVID-19 vaccine – Long term immune decline and breakthrough infections
Since the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was reported, and decision making regarding a booster remains a top priority worldwide, a decision that should be made based on breakthrough infection rate and ant...
Saved in:
Published in | Vaccine Vol. 39; no. 48; pp. 6984 - 6989 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier Ltd
26.11.2021
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Since the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was reported, and decision making regarding a booster remains a top priority worldwide, a decision that should be made based on breakthrough infection rate and antibody titer decline overtime.
We conducted a 5-month longitudinal prospective study involving vaccinated healthcare personnel, who were tested monthly for antibody titer, and sampled biweekly and on clinical indication for SARS-COV-2 polymerase chain reaction (PCR), to determine antibody decline and breakthrough infection.
100 participants were recruited to the study. Antibody titer reached the climate after one month of the second dose of the vaccine, and declined rapidly thereafter: the median antibody levels were 895; 22,266; 9,682; 2,554 and 1,401 AU/ml in the day of the second dose, and in one month interval thereafter, respectively. In other words, four months after vaccination, the mean antibody level was 6% of the peak levels. During the study period, 4 breakthrough infections were diagnosed, 2 of which were asymptomatic, and the remaining two were mild cases; sharp elevation of antibody titer was seen after infection.
Antibody titer drops rapidly one month after the second dose of the vaccine. All infections within the study period were mild or asymptomatic, after which titer elevations were seen. |
---|---|
AbstractList | BackgroundSince the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was reported, and decision making regarding a booster remains a top priority worldwide, a decision that should be made based on breakthrough infection rate and antibody titer decline overtime.MethodsWe conducted a 5-month longitudinal prospective study involving vaccinated healthcare personnel, who were tested monthly for antibody titer, and sampled biweekly and on clinical indication for SARS-COV-2 polymerase chain reaction (PCR), to determine antibody decline and breakthrough infection.Results100 participants were recruited to the study. Antibody titer reached the climate after one month of the second dose of the vaccine, and declined rapidly thereafter: the median antibody levels were 895; 22,266; 9,682; 2,554 and 1,401 AU/ml in the day of the second dose, and in one month interval thereafter, respectively. In other words, four months after vaccination, the mean antibody level was 6% of the peak levels. During the study period, 4 breakthrough infections were diagnosed, 2 of which were asymptomatic, and the remaining two were mild cases; sharp elevation of antibody titer was seen after infection.ConclusionAntibody titer drops rapidly one month after the second dose of the vaccine. All infections within the study period were mild or asymptomatic, after which titer elevations were seen. Since the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was reported, and decision making regarding a booster remains a top priority worldwide, a decision that should be made based on breakthrough infection rate and antibody titer decline overtime. We conducted a 5-month longitudinal prospective study involving vaccinated healthcare personnel, who were tested monthly for antibody titer, and sampled biweekly and on clinical indication for SARS-COV-2 polymerase chain reaction (PCR), to determine antibody decline and breakthrough infection. 100 participants were recruited to the study. Antibody titer reached the climate after one month of the second dose of the vaccine, and declined rapidly thereafter: the median antibody levels were 895; 22,266; 9,682; 2,554 and 1,401 AU/ml in the day of the second dose, and in one month interval thereafter, respectively. In other words, four months after vaccination, the mean antibody level was 6% of the peak levels. During the study period, 4 breakthrough infections were diagnosed, 2 of which were asymptomatic, and the remaining two were mild cases; sharp elevation of antibody titer was seen after infection. Antibody titer drops rapidly one month after the second dose of the vaccine. All infections within the study period were mild or asymptomatic, after which titer elevations were seen. |
Author | Saffuri, Amer Elemy, Ameer Hakim, Fahed Hanna, Ayman Shkeiri, Rashed Abu Ahmad, Yara Khoury, Johad Abu-Sinni, Majdole Najjar-Debbiny, Ronza Jabbour, Adel |
Author_xml | – sequence: 1 givenname: Johad orcidid: 0000-0001-8048-1542 surname: Khoury fullname: Khoury, Johad email: jihadfk@gmail.com organization: Pulmonology Division, Lady Davis- Carmel Medical Center, Haifa, Israel, and EMMS Nazaerth, Israel – sequence: 2 givenname: Ronza surname: Najjar-Debbiny fullname: Najjar-Debbiny, Ronza organization: Ruth and Bruce Rappaport faculty of Medicine, Haifa, Israel – sequence: 3 givenname: Ayman surname: Hanna fullname: Hanna, Ayman organization: Internal Medicine department, EMMS, Nazareth, Israel – sequence: 4 givenname: Adel surname: Jabbour fullname: Jabbour, Adel organization: Medical laboratory, EMMS, Nazareth, Israel – sequence: 5 givenname: Yara surname: Abu Ahmad fullname: Abu Ahmad, Yara organization: Internal Medicine department, EMMS, Nazareth, Israel – sequence: 6 givenname: Amer surname: Saffuri fullname: Saffuri, Amer organization: Internal Medicine department, EMMS, Nazareth, Israel – sequence: 7 givenname: Majdole surname: Abu-Sinni fullname: Abu-Sinni, Majdole organization: Pulmonology Division, Lady Davis- Carmel Medical Center, Haifa, Israel, and EMMS Nazaerth, Israel – sequence: 8 givenname: Rashed surname: Shkeiri fullname: Shkeiri, Rashed organization: Pulmonology Division, Lady Davis- Carmel Medical Center, Haifa, Israel, and EMMS Nazaerth, Israel – sequence: 9 givenname: Ameer surname: Elemy fullname: Elemy, Ameer organization: Hospital Director Assistant, EMMS, Nazareth, Israel – sequence: 10 givenname: Fahed surname: Hakim fullname: Hakim, Fahed organization: Pediatric Pulmonology, The Brain, Sleep and Immunity Laboratory. EMMS, Nazareth, Israel |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34763949$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc2O0zAUhS00iOkUHgEUiQ2bFDv-SbwBofJXqdJsALGzHPumdUnswU4qsZt3mDfkSXDUMgI2rCzd-93je8-5Qhc-eEDoKcErgol4eVgdtTHOw6rCFcm1FabNA7QgTU3LipPmAi1wJVjJCP56ia5SOmCMOSXyEbqkrBZUMrlAm_X1l83bksjiLFf8vL0rtsHvihHiULhhmHLRgunnpva2aCPob-M-hmm3L5zvwIwu-PQYPex0n-DJ-V2iz-_ffVp_LLfXHzbrN9vScEHGsuVUW6ZrLg1AZTuwDa0xo4JoaDiXLbNWd1AzoNYyIlrccsGZYaTKu2NKl-jVSfdmagewBvwYda9uoht0_KGCdurvjnd7tQtHldUFlzwLvDgLxPB9gjSqwSUDfa89hCmpisuaNVJki5bo-T_oIUzR5_NmSvK64Yxkip8oE0NKEbr7ZQhWc1jqoM7uqjmsuZzDynPP_rzkfup3Ohl4fQIg-3l0EFUyDrwB62J2Xdng_vPFL4Vkqo8 |
CitedBy_id | crossref_primary_10_1002_mco2_460 crossref_primary_10_7759_cureus_32089 crossref_primary_10_7143_jhep_49_462 crossref_primary_10_1371_journal_pone_0291670 crossref_primary_10_3390_healthcare10061085 crossref_primary_10_1093_ofid_ofad073 crossref_primary_10_1128_spectrum_04292_22 crossref_primary_10_1111_all_15373 crossref_primary_10_3390_pathogens11121531 crossref_primary_10_2147_RMHP_S388668 crossref_primary_10_1016_j_hlife_2024_03_006 crossref_primary_10_3389_fimmu_2022_949248 crossref_primary_10_1016_j_vaccine_2023_05_041 crossref_primary_10_1002_jgf2_688 crossref_primary_10_29407_ja_v6i3_16772 crossref_primary_10_1002_cam4_6781 crossref_primary_10_3389_fimmu_2023_1246751 crossref_primary_10_3390_vaccines11050920 crossref_primary_10_1016_j_imj_2022_10_001 crossref_primary_10_3390_vaccines10071139 crossref_primary_10_3390_vaccines11010051 crossref_primary_10_1093_infdis_jiac403 crossref_primary_10_3390_vaccines11040842 crossref_primary_10_1021_acsnano_4c02434 crossref_primary_10_1007_s12038_023_00355_1 crossref_primary_10_1038_s41467_022_35480_2 crossref_primary_10_1016_j_heliyon_2022_e10583 crossref_primary_10_1016_j_hlpt_2023_100801 crossref_primary_10_3389_fmed_2022_972083 crossref_primary_10_3389_fpubh_2022_945448 crossref_primary_10_1186_s13690_022_00935_x crossref_primary_10_1002_jmv_29122 crossref_primary_10_1515_cclm_2021_1247 crossref_primary_10_1016_j_envres_2022_114252 crossref_primary_10_1016_j_molimm_2023_03_007 crossref_primary_10_1159_000536308 crossref_primary_10_1080_22221751_2022_2053365 crossref_primary_10_1080_23744235_2022_2097304 crossref_primary_10_1371_journal_pone_0301383 crossref_primary_10_3389_fpubh_2022_987452 crossref_primary_10_3389_fpubh_2022_1010336 crossref_primary_10_1093_cvr_cvac115 crossref_primary_10_1186_s12879_022_07377_4 crossref_primary_10_1016_j_jiac_2023_11_014 crossref_primary_10_3389_fimmu_2022_986085 crossref_primary_10_3390_v14102188 crossref_primary_10_1186_s12916_022_02587_8 crossref_primary_10_1002_jmv_27590 crossref_primary_10_1038_s41541_023_00724_9 crossref_primary_10_3390_vaccines10050755 crossref_primary_10_1111_tmi_13869 crossref_primary_10_3390_jcm11247534 crossref_primary_10_1002_jmv_27637 crossref_primary_10_1016_j_jiph_2023_12_026 crossref_primary_10_3389_fimmu_2023_1106664 crossref_primary_10_1016_j_tmaid_2023_102563 crossref_primary_10_1038_s41541_022_00532_7 crossref_primary_10_3390_pharmaceutics15051412 crossref_primary_10_1002_jmv_27688 crossref_primary_10_3389_fpubh_2024_1394762 crossref_primary_10_1038_s41467_022_33076_4 crossref_primary_10_1371_journal_pone_0274553 crossref_primary_10_1371_journal_pone_0282520 crossref_primary_10_1016_S1473_3099_23_00650_3 crossref_primary_10_3390_biology12101293 crossref_primary_10_1080_22221751_2022_2152388 |
Cites_doi | 10.1056/NEJMoa2035389 10.1001/jama.2021.7152 10.1056/NEJMoa2109072 10.1056/NEJMoa2027906 10.1056/NEJMoa2114114 10.1056/NEJMc2103916 10.1056/NEJMoa2034577 |
ContentType | Journal Article |
Copyright | 2021 Elsevier Ltd Copyright © 2021 Elsevier Ltd. All rights reserved. 2021. Elsevier Ltd 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd |
Copyright_xml | – notice: 2021 Elsevier Ltd – notice: Copyright © 2021 Elsevier Ltd. All rights reserved. – notice: 2021. Elsevier Ltd – notice: 2021 Elsevier Ltd. All rights reserved. 2021 Elsevier Ltd |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM |
DOI | 10.1016/j.vaccine.2021.10.038 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database PML(ProQuest Medical Library) Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Research Library Prep ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Central Basic ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Research Library Prep MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1873-2518 |
EndPage | 6989 |
ExternalDocumentID | 10_1016_j_vaccine_2021_10_038 34763949 S0264410X21013700 |
Genre | Journal Article |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AAXUO ABBQC ABFNM ABFRF ABJNI ABKYH ABLVK ABMAC ABMZM ABRWV ABUWG ABYKQ ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADBBV ADEZE ADFRT AEBSH AEFWE AEKER AENEX AESVU AEVXI AEXOQ AFCTW AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFLBG EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LCYCR LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PQQKQ PROAC PSQYO Q38 QYZTP ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- AAHBH AAXKI AKRWK ALIPV CGR CUY CVF ECM EIF NPM RIG .GJ 0SF 29Q 3V. AAQXK AAYXX ABXDB ADMUD ADVLN AFJKZ AGHFR AHHHB ASPBG AVWKF AZFZN CITATION EJD FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- SAE SEW SIN SVS WUQ XPP ZGI ZXP 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PQEST PQUKI PRINS Q9U 7X8 5PM |
ID | FETCH-LOGICAL-c561t-b53ad4a759cee2dfed83704361ae8559b4ddafe74e3dd416b0b5654c412319033 |
IEDL.DBID | AIKHN |
ISSN | 0264-410X |
IngestDate | Tue Sep 17 21:25:40 EDT 2024 Fri Aug 16 06:08:38 EDT 2024 Fri Sep 13 05:38:51 EDT 2024 Thu Sep 26 18:08:29 EDT 2024 Sat Sep 28 08:17:55 EDT 2024 Fri Feb 23 02:41:17 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 48 |
Keywords | COVID Vaccine Immunogenicity Antibody Booster |
Language | English |
License | Copyright © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c561t-b53ad4a759cee2dfed83704361ae8559b4ddafe74e3dd416b0b5654c412319033 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors are equally contributed to the manuscript. |
ORCID | 0000-0001-8048-1542 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8556595 |
PMID | 34763949 |
PQID | 2599578541 |
PQPubID | 105530 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8556595 proquest_miscellaneous_2597489676 proquest_journals_2599578541 crossref_primary_10_1016_j_vaccine_2021_10_038 pubmed_primary_34763949 elsevier_sciencedirect_doi_10_1016_j_vaccine_2021_10_038 |
PublicationCentury | 2000 |
PublicationDate | 2021-11-26 |
PublicationDateYYYYMMDD | 2021-11-26 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-26 day: 26 |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands – name: Kidlington |
PublicationTitle | Vaccine |
PublicationTitleAlternate | Vaccine |
PublicationYear | 2021 |
Publisher | Elsevier Ltd Elsevier Limited |
Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
References | Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, et al Angel, Spitzer, Henig, Saiag, Sprecher, Padova (b0015) 2021; 325 2021. Polack, Thomas, Kitchin, Absalon, Gurtman, Lockhart (b0020) 2020; 383 20.21 Chemaitelly, Tang, Hasan, AlMukdad, Yassine, Benslimane (b0035) 2021 Walsh, Frenck, Falsey, Kitchin, Absalon, Gurtman (b0025) 2020; 383 Doria-Rose, Suthar, Makowski, O’Connell, McDermott, Flach (b0045) 2021; 384 Baden, El Sahly, Essink, Kotloff, Frey, Novak (b0005) 2021; 384 CDC) CoDCaP Yang, Costa, Racine-Brzostek, Acker, Yee, Chen (b0010) 2021; 4 Bergwerk, Gonen, Lustig, Amit, Lipsitch, Cohen (b0040) 2021; 385 Angel (10.1016/j.vaccine.2021.10.038_b0015) 2021; 325 Chemaitelly (10.1016/j.vaccine.2021.10.038_b0035) 2021 10.1016/j.vaccine.2021.10.038_b0050 Polack (10.1016/j.vaccine.2021.10.038_b0020) 2020; 383 Walsh (10.1016/j.vaccine.2021.10.038_b0025) 2020; 383 10.1016/j.vaccine.2021.10.038_b0030 Doria-Rose (10.1016/j.vaccine.2021.10.038_b0045) 2021; 384 Bergwerk (10.1016/j.vaccine.2021.10.038_b0040) 2021; 385 Baden (10.1016/j.vaccine.2021.10.038_b0005) 2021; 384 Yang (10.1016/j.vaccine.2021.10.038_b0010) 2021; 4 |
References_xml | – volume: 384 start-page: 403 year: 2021 end-page: 416 ident: b0005 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med contributor: fullname: Novak – volume: 4 start-page: e214302 year: 2021 ident: b0010 article-title: Association of Age With SARS-CoV-2 Antibody Response publication-title: JAMANetw Open contributor: fullname: Chen – volume: 325 start-page: 2457 year: 2021 ident: b0015 article-title: Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers publication-title: JAMA contributor: fullname: Padova – year: 2021 ident: b0035 article-title: Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar publication-title: N Engl J Med contributor: fullname: Benslimane – volume: 385 start-page: 1474 year: 2021 end-page: 1484 ident: b0040 article-title: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers publication-title: N Engl J Med contributor: fullname: Cohen – volume: 383 start-page: 2603 year: 2020 end-page: 2615 ident: b0020 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med contributor: fullname: Lockhart – volume: 383 start-page: 2439 year: 2020 end-page: 2450 ident: b0025 article-title: Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates publication-title: N Engl J Med contributor: fullname: Gurtman – volume: 384 start-page: 2259 year: 2021 end-page: 2261 ident: b0045 article-title: Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 publication-title: N Engl J Med contributor: fullname: Flach – volume: 384 start-page: 403 issue: 5 year: 2021 ident: 10.1016/j.vaccine.2021.10.038_b0005 article-title: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2035389 contributor: fullname: Baden – volume: 325 start-page: 2457 issue: 24 year: 2021 ident: 10.1016/j.vaccine.2021.10.038_b0015 article-title: Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers publication-title: JAMA doi: 10.1001/jama.2021.7152 contributor: fullname: Angel – ident: 10.1016/j.vaccine.2021.10.038_b0050 – volume: 385 start-page: 1474 issue: 16 year: 2021 ident: 10.1016/j.vaccine.2021.10.038_b0040 article-title: Covid-19 Breakthrough Infections in Vaccinated Health Care Workers publication-title: N Engl J Med doi: 10.1056/NEJMoa2109072 contributor: fullname: Bergwerk – volume: 383 start-page: 2439 issue: 25 year: 2020 ident: 10.1016/j.vaccine.2021.10.038_b0025 article-title: Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates publication-title: N Engl J Med doi: 10.1056/NEJMoa2027906 contributor: fullname: Walsh – ident: 10.1016/j.vaccine.2021.10.038_b0030 – year: 2021 ident: 10.1016/j.vaccine.2021.10.038_b0035 article-title: Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar publication-title: N Engl J Med doi: 10.1056/NEJMoa2114114 contributor: fullname: Chemaitelly – volume: 384 start-page: 2259 issue: 23 year: 2021 ident: 10.1016/j.vaccine.2021.10.038_b0045 article-title: Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMc2103916 contributor: fullname: Doria-Rose – volume: 4 start-page: e214302 issue: 3 year: 2021 ident: 10.1016/j.vaccine.2021.10.038_b0010 article-title: Association of Age With SARS-CoV-2 Antibody Response publication-title: JAMANetw Open contributor: fullname: Yang – volume: 383 start-page: 2603 issue: 27 year: 2020 ident: 10.1016/j.vaccine.2021.10.038_b0020 article-title: Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine publication-title: N Engl J Med doi: 10.1056/NEJMoa2034577 contributor: fullname: Polack |
SSID | ssj0005319 |
Score | 2.6132221 |
Snippet | Since the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was reported, and... BackgroundSince the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was... BACKGROUNDSince the introduction of BNT162b2 mRNA COVID-19 vaccine by Pfizer in late 2020, efficacy and immunogenicity waning of COVID-19 vaccines was... |
SourceID | pubmedcentral proquest crossref pubmed elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 6984 |
SubjectTerms | Age groups Antibodies Antibody Asymptomatic BNT162 Vaccine Booster Coronaviruses COVID COVID-19 COVID-19 Vaccines Decision making Drug dosages Humans Immunogenicity Immunogenicity, Vaccine Infections mRNA Polymerase chain reaction Prospective Studies SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Short Communication Vaccine Vaccines |
SummonAdditionalLinks | – databaseName: AUTh Library subscriptions: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwEB6VViAuCJZHAwUZCfVU7ya28zpVUFptES0r1FZ7i-zYoS1StrBbpN74D_zD_hJmEmdDAcE1jiXbM56HZ-YbgFeyVFUYm5S7sAq5SkTFc1HlPNah0dJGxjRQSgeHyfhYvZvG0xUYd7UwlFbZycRGUNtZSW_kI0HIWGkWq2ikDb0ClIvR9sUXTv2jKM7qm2ncgjURKQrYrr3ZPZx87NM9ZNPkA10OxVUUTvtqntH58JsuKYyN7qKIhpTsReUqf9dTf9qhv6dT_qKf9u7DPW9YstctJzyAFVcP4HbbavJqAHcOfBB9AJuTFq76aosd9dVX8y22ySY9kDXOGZxQrkxTsMu66Q9hf-fDyf5bHuXM74ddf__B3s_qT4zEPDujihPHrKOiS8d0bRm63fqz7wjEuvSvev4Ijvd2j3bG3Ddk4CWaWQtuYqmt0mmco2oVtnKWoHOUTCLtMnRNjLJWVy5VTlqLRDChQXtRlQrVIxoeUj6G1XpWu3VgIsm0UznygkpUZkvjdFqlsbCuQh8qTwMYdsdfXLS4G0WXkHZe-P0VRC_6jPQKIOuIVHjjoTUKCtQN_5u60RG18Dd4XvT8FsDL5TDePQqo6NrNLpt_CLwnSZMAnrQ8sFysVCi5c5UHkN7gjuUPhOt9c6Q-O23wvfEoCeXx6b-X9Qzu0h6oLlIkG7C6-HrpnqOBtDAvPO__BLfyEew priority: 102 providerName: ProQuest |
Title | COVID-19 vaccine – Long term immune decline and breakthrough infections |
URI | https://dx.doi.org/10.1016/j.vaccine.2021.10.038 https://www.ncbi.nlm.nih.gov/pubmed/34763949 https://www.proquest.com/docview/2599578541/abstract/ https://search.proquest.com/docview/2597489676 https://pubmed.ncbi.nlm.nih.gov/PMC8556595 |
Volume | 39 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VVKBeEISXoaBFQj3Vie1de-1jCa0SoCGCtsrN2vWuIa3kVCRF6gXxH_iH_BJm7HVCAAmJix-7O9I-56Gd-QbgBS9EGcRa-jYoA18kUelnUZn5sQq04ibUuoZSOh4nw1PxehpPt2DQxsKQW6Xj_Q1Pr7m1K-m72exfzmb9D0Ety4MpGi0hlwHa7dsojoTowPbB6M1wvPb04HV-D2rvE8E6kKd_3vuiCrrBRksxCnvk50WRKn8XUX-qoL97Uv4imo7uwG2nU7KDptt3YctWXbjZZJm87sKtY3d_3oW9SYNUfb3PTtaBV4t9tscmawxrpOmekZtMHavLWvJ7MBq8Oxu98sOMufGwH9--s7fz6iMjDs9mFGximbEUb2mZqgxDi1tduGRArPX8qhb34fTo8GQw9F0uBr9ADWvp65grI5SMM5SqkSmtIdQcwZNQ2RStEi2MUaWVwnJjUMnTgUZVURQCJSPqHJw_gE41r-wjYFGSKisy3AYiEakptFWylHFkbInmUyY96LXTn182kBt564t2nrvx5bReVIzr5UHaLlK-sXdyFAv_It1tFzV3h3eRRwTCJtNYhB48X1XjsaO7FFXZ-VXdhnB7Epl48LDZA6vOcoFMOxOZB3Jjd6waEKT3Zk01-1RDe-NUEsDj4_8f0RPYoT8Kl4ySXegsP1_Zp6g3LfUzuNH7GuJTTiU-0wF-NycF3y8Px5P3PwGi9Bxn |
link.rule.ids | 230,315,786,790,891,4521,12083,12250,21416,24144,27957,27958,31754,31755,33301,33302,33779,33780,43345,43614,43840,45620,45714,74102,74371,74659 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1LbxMxEB5BKh4XBIHCQgEjoZ7qdHftfZ0QlFYJJCFCaZXbyl57-0DaFJIi9cZ_4B_yS5jZ9SYUEFzXa8n22J5vPDPfALwUhSz9SCfc-qXPZRyWPAvLjEfK10qYQOuaSmk0jvuH8t0smrkHt4ULq2zvxPqiNvOC3sh3Q2LGStJIBq_OP3OqGkXeVVdC4zpsSIGmSgc23uyPJx_XQR6iLu2BhobkMvBn6xye3bPeV1WQ8xqNxDDoUYgXJan8XTv9iT5_D6L8RSsd3IU7Dk6y143878E1W3XhRlNg8rILN0fOdd6F7UlDUn25w6brnKvFDttmkzV9NfbpHlGETJ2my9ru92Gw9-Fo8JYHGXPzYT--fWfDeXXM6HJnp5RnYpmxlGppmaoMQ2NbfXJ1gFgb9FUtHsDhwf50r89dGQZeILhach0JZaRKogwVamhKa4gwR4o4UDZFg0RLY1RpE2mFMYjvtK8RJcpColJEuCHEJnSqeWUfAQvjVFmZ4Q6QsUxNoa1KyiQKjS3RcsoSD3rt8ufnDdtG3oahneVufjnJiz6jvDxIWyHlDjI0UCBHjfC_rlutUHN3bhf5epd58GLVjCeO3CiqsvOL-h-i7ImT2IOHzR5YDVZIvK8zmXmQXNkdqx-IzftqS3V6UrN641ISt-Pjfw_rOdzqT0fDfDgYv38Ct2k-lBkZxlvQWX65sE8RIi31M3cOfgK-1BEf |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3BbtQwEB1BERUXBAuUlAJGQj3Vu0nsxMkJoS2rLrRlD221t8iOHWiRsqW7ReqNf-AP-RJmEme3BQTXJJbieMbzJn7zBuC1KGUVJkZxF1Yhl2lc8Tyucp7o0GhhI2MaKaWDw3TvWL6fJlPPf5p7WmW3JzYbtZ2V9I98EJMylsoSGQ0qT4uY7I7enH_l1EGKTlp9O43bcAejoiInzYbX6B6iafKBKYfkMgqnq2qewVn_my7pGBvTxTjqE9mLylX-Hqf-xKG_0ymvxafRA7jvgSV721rCQ7jl6h7cbVtNXvVg_cAfovdge9LKVV_tsKNV9dV8h22zyUrIGsf0Togr0xTssm74IxgPP56Md3mUMz8f9vP7D7Y_qz8x2ubZKVWcOGYdFV06pmvLMO3WX3xHINbRv-r5YzgevTsa7nHfkIGXCLMW3CRCW6lVkmNojW3lLEnnSJFG2mWYmhhpra6ckk5Yi0jPhAbxoiwlhkcEHkI8gbV6VrunwOI0007maAsylZktjdOqUklsXYU5VK4C6HefvzhvdTeKjpB2Vvj5FbRedBnXK4CsW6TCg4cWFBQYG_43dKtb1MJ78LxY2VsAr5a30ffoQEXXbnbZPEPiPalKA9hobWD5skLizp3LPAB1wzqWD5Cu98079ennRt8bPyWpPG7--7Vewjo6QLE_PvzwDO7RdKhEMk63YG1xcemeI1ZamBeNE_wCmR4TuQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+vaccine+-+Long+term+immune+decline+and+breakthrough+infections&rft.jtitle=Vaccine&rft.au=Khoury%2C+Johad&rft.au=Najjar-Debbiny%2C+Ronza&rft.au=Hanna%2C+Ayman&rft.au=Jabbour%2C+Adel&rft.date=2021-11-26&rft.eissn=1873-2518&rft.volume=39&rft.issue=48&rft.spage=6984&rft_id=info:doi/10.1016%2Fj.vaccine.2021.10.038&rft_id=info%3Apmid%2F34763949&rft.externalDocID=34763949 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0264-410X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0264-410X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0264-410X&client=summon |